EPS for Tetraphase Pharmaceuticals, Inc. (TTPH) Expected At $-0.64

February 15, 2018 - By Darrin Black

 EPS for Tetraphase Pharmaceuticals, Inc. (TTPH) Expected At $ 0.64
Investors sentiment increased to 2.21 in 2017 Q3. Its up 0.90, from 1.31 in 2017Q2. It is positive, as 10 investors sold Tetraphase Pharmaceuticals, Inc. shares while 14 reduced holdings. 19 funds opened positions while 34 raised stakes. 29.38 million shares or 42.90% more from 20.56 million shares in 2017Q2 were reported.
47,051 were accumulated by Goldman Sachs Group Inc Inc Inc. Baker Bros L P holds 0.05% or 935,000 shares in its portfolio. Tudor Corp Et Al holds 0.02% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 100,000 shares. Aqr Ltd Limited Liability Company holds 0% or 163,266 shares in its portfolio. Hudson Bay Cap Management L P has invested 0.1% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Schwab Charles Inv Management Inc holds 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 217,079 shares. Moreover, Rock Springs Capital Mngmt Limited Partnership has 0.3% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 950,000 shares. Fmr Ltd Liability has invested 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Jpmorgan Chase invested 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Point72 Asia (Hong Kong) Limited reported 552 shares. Barclays Public Ltd Liability Co stated it has 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Parallax Volatility Advisers L P has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Balyasny Asset Management Ltd Liability has invested 0.01% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Dimensional Fund Advsr Ltd Partnership holds 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 1.46 million shares. Art Limited Liability Corporation reported 18,457 shares.

Since August 17, 2017, it had 0 buys, and 3 sales for $203,932 activity.

Analysts expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report $-0.64 EPS on March, 14.They anticipate $0.03 EPS change or 4.92 % from last quarter’s $-0.61 EPS. After having $-0.63 EPS previously, Tetraphase Pharmaceuticals, Inc.’s analysts see 1.59 % EPS growth. The stock increased 1.40% or $0.03 during the last trading session, reaching $2.18. About 3.03M shares traded or 299.63% up from the average. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has risen 106.58% since February 15, 2017 and is uptrending. It has outperformed by 89.88% the S&P500.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Among 15 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 6 have Buy rating, 0 Sell and 9 Hold. Therefore 40% are positive. Tetraphase Pharmaceuticals had 29 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Neutral” rating by Gabelli on Friday, May 13. The rating was upgraded by Stifel Nicolaus on Wednesday, July 26 to “Buy”. As per Friday, March 10, the company rating was upgraded by BMO Capital Markets. Stifel Nicolaus downgraded Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Wednesday, September 9 to “Hold” rating. The company was maintained on Thursday, August 6 by Brean Capital. Nomura downgraded the shares of TTPH in report on Wednesday, September 9 to “Neutral” rating. Needham downgraded the stock to “Hold” rating in Wednesday, September 9 report. The company was maintained on Wednesday, February 14 by SunTrust. As per Wednesday, February 14, the company rating was downgraded by BMO Capital Markets. The company was maintained on Thursday, August 3 by Needham.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $112.48 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

Another recent and important Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news was published by Nasdaq.com which published an article titled: “Mid-Day Market Update: US Stocks Turn Higher; Tetraphase Pharmaceuticals …” on February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.